EUVIMEDEUVIMED entdecken
Crossref

Clinical impact of a dose-escalation strategy for lenvatinib in differentiated thyroid cancer

Ryutaro Onaga, Tomohiro Enokida, Susumu Okano, Takao Fujisawa, Nobukazu Tanaka, Yuta Hoshi, Takuma Kishida, Hideki Tanaka, Masanobu Sato, Naohiro Takeshita, Ryo Kuboki, Hiroshi Nishino und 2 weitere

International Journal of Clinical Oncology · 2024

DOI: 10.1007/s10147-024-02581-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2024. Verfasst von Ryutaro Onaga und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa-shi, Chiba, 277-8577, Japan. Hauptthemen laut MEDLINE: Quinolines, Thyroid Neoplasms, Phenylurea Compounds. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Treatment options for patients with differentiated thyroid cancer (DTC) who experience disease progression on lenvatinib treatment are limited. Although dose escalation of treatment with tyrosine kinase inhibitors at disease progression has been reported across cancer types, clinical significance in patients with DTC has not been investigated. METHODS: We retrospectively reviewed patients with DTC who experienced disease progression on lenvatinib treatment from September 2011 to June 2022. We compared subjects who received dose-escalation treatment with standard treatment of termination at the time of initial disease progression. The escalated dose was decided by referencing to the previous effective and tolerated dose. RESULTS: Thirty-three patients were identified, 15 with dose escalation and 18 with lenvatinib termination. In both groups, the starting dose of lenvatinib was 24 mg/day, and the median dose at initial disease progression was 10 mg/day. In the former, the median dose escalation was 6 mg/day (range: 4-12). Objective response rate, clinical benefit rate by escalation, and median treatment duration of the dose-escalation phase were 13.3%, 73.3%, and 9.9 months (95% confidence interval [CI] 5.71-27.6), respectively. Median overall survival from initial disease progression was significantly longer in the dose-escalation group (median OS: 20.4 months [95% CI 7.0-NA] vs. 3.9 months [95% CI 1.7-7.9], log-rank p-value; 0.0004, hazard ratio; 0.22 [95% CI 0.09-0.55]). There were no grade 5 adverse events, and one patient discontinued due to a grade 3 lung abscess. CONCLUSION: The dose-escalation strategy appears to be a safe and effective treatment option after disease progression in patients treated with lenvatinib for DTC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

QuinolinesThyroid NeoplasmsPhenylurea CompoundsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultDisease ProgressionProtein Kinase InhibitorsDose-Response Relationship, DrugAntineoplastic AgentsAged, 80 and over

Stichwörter der Autor:innen

Differentiated thyroid cancerDose escalationLenvatinibTyrosine kinase inhibitor

Substanzen

lenvatinibQuinolinesPhenylurea CompoundsProtein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa-shi, Chiba, 277-8577, Japan.
  • Department of Otolaryngology and Head and Neck Surgery, Jichi Medical University, Tochigi, Japan.
  • Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Department of Otolaryngology, Jikei University, Tokyo, Japan.
  • Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa-shi, Chiba, 277-8577, Japan. matahara@east.ncc.go.jp.

Zitieren

APA

Onaga, R., Enokida, T., Okano, S., Fujisawa, T., Tanaka, N., Hoshi, Y., Kishida, T., Tanaka, H., Sato, M., Takeshita, N., Kuboki, R., Nishino, H., Ito, M., & Tahara, M. (2024). Clinical impact of a dose-escalation strategy for lenvatinib in differentiated thyroid cancer. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02581-5

Vancouver

Onaga R, Enokida T, Okano S, Fujisawa T, Tanaka N, Hoshi Y, et al. Clinical impact of a dose-escalation strategy for lenvatinib in differentiated thyroid cancer. International Journal of Clinical Oncology. 2024. doi:10.1007/s10147-024-02581-5

BibTeX
@article{Onaga2024,
  author = {Onaga, Ryutaro and Enokida, Tomohiro and Okano, Susumu and Fujisawa, Takao and Tanaka, Nobukazu and Hoshi, Yuta and Kishida, Takuma and Tanaka, Hideki and Sato, Masanobu and Takeshita, Naohiro and Kuboki, Ryo and Nishino, Hiroshi and Ito, Makoto and Tahara, Makoto},
  title = {Clinical impact of a dose-escalation strategy for lenvatinib in differentiated thyroid cancer},
  journal = {International Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1007/s10147-024-02581-5}
}
Kostenlos starten →